Baker BROS. Advisors LP Has $9.38 Million Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN)

Baker BROS. Advisors LP lifted its position in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 2.9% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,743,725 shares of the company’s stock after buying an additional 48,431 shares during the quarter. Baker BROS. Advisors LP owned about 3.08% of Design Therapeutics worth $9,381,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Price T Rowe Associates Inc. MD acquired a new stake in Design Therapeutics in the 1st quarter worth about $45,000. Paloma Partners Management Co bought a new position in shares of Design Therapeutics during the third quarter worth approximately $64,000. SG Americas Securities LLC bought a new position in shares of Design Therapeutics during the third quarter worth approximately $66,000. American Century Companies Inc. acquired a new stake in shares of Design Therapeutics in the second quarter valued at approximately $71,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Design Therapeutics in the third quarter valued at approximately $71,000. Institutional investors own 56.64% of the company’s stock.

Design Therapeutics Stock Up 0.5 %

DSGN opened at $6.00 on Monday. The stock has a market capitalization of $339.73 million, a price-to-earnings ratio of -7.06 and a beta of 1.83. Design Therapeutics, Inc. has a twelve month low of $2.16 and a twelve month high of $7.77. The company has a 50-day simple moving average of $5.55 and a 200 day simple moving average of $4.77.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Design Therapeutics in a research note on Tuesday, August 6th.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.